Evidence map›Paper›PMID 27827375›Full record

ArticleMucosal immunology2017

Predominance of weakly cytotoxic, T-bet

B E Kiniry, A Ganesh, J W Critchfield, P W Hunt, F M Hecht, M Somsouk, S G Deeks, B L Shacklett

Open access · hybridAbstract read
In one paragraph

Article in Mucosal immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. CD8MedComm · 2026
    Review
  3. Review
  4. Gastrointestinal MAIT cells in chronic HIV-1 infection.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Article
  5. Article
  6. Therapeutic CD8Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. The precursors of CD8Nature reviews. Immunology · 2022
    Review
  13. Article
  14. Review
  15. The CD8Microbiology and molecular biology reviews : MMBR · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

B E KiniryDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, California, USA.
A GaneshDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, California, USA.
J W CritchfieldDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, California, USA.
P W HuntDivision of Experimental Medicine, San Francisco General Hospital, San Francisco, California, USA.
F M HechtPositive Health Program, Department of Medicine, San Francisco General Hospital, San Francisco, California, USA.
M SomsoukDivision of Gastroenterology, Department of Medicine, San Francisco General Hospital, San Francisco, California, USA.
S G DeeksPositive Health Program, Department of Medicine, San Francisco General Hospital, San Francisco, California, USA.
B L ShacklettDepartment of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, California, USA.
San Francisco General Hospital · USUniversity of California, Davis · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI PRIMO N. LARA · 2002 to 2026
$84.9M
HIV-Specific T Cell Responses in Rectal MucosaR01AI057020 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI SHACKLETT, BARBARA L. · 2003 to 2016
$6.2M
Mentoring and Research in Integrative MedicineK24AT007827 · NCCIH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HECHT, FREDERICK M · 2013 to 2022
$1.8M
UC Davis Shared Astrios Cell SorterS10OD018223 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHACKLETT, BARBARA L. · 2015 to 2015
$555k
Shared LSRII Cytometer Equipment Application - UC Davis Stem Cell ProgramS10RR026825 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NOLTA, JAN A. · 2010 to 2010
$500k
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR012088 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI CURRY, FITZ-ROY E · 1996 to 1996
–
NCCIH NIH HHS K24 AT007827NCI NIH HHS P30 CA093373NCRR NIH HHS C06 RR012088NCRR NIH HHS S10 RR026825NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI057020NIH HHS S10 OD018223
6 · The paper itself

Abstract

The gastrointestinal mucosa is an important site of HIV acquisition, viral replication, and pathogenesis. Immune cells in mucosal tissues frequently differ in phenotype and function from their non-mucosal counterparts. Although perforin-mediated cytotoxicity as measured in blood is a recognized correlate of HIV immune control, its role in gastrointestinal tissues is unknown. We sought to elucidate the cytotoxic features of rectal mucosal CD8

Indexed as

AIDS VaccinesAnti-Retroviral AgentsCD8-Positive T-LymphocytesCells, CulturedCellular MicroenvironmentCytotoxicity, ImmunologicFemaleGranzymesHIV InfectionsHumansIntestinal MucosaMalePerforinRectumT-bet Transcription FactorT-Box Domain ProteinsAIDS VaccinesAnti-Retroviral AgentsEOMES protein, humanGranzymesPerforinT-bet Transcription FactorT-Box Domain ProteinsTransforming Growth Factor beta

Identifiers

PMID27827375
PMCPMC5423867
OpenAlexW2552551254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.